CAD & Atherosclerosis
From the Journals
Test Lp(a) levels to inform ASCVD management: NLA statement
“The question in the scientific community is: What role does that particular biomarker play in terms of causing serious heart disease, stroke, and...
Conference Coverage
No invasive strategy benefit at 5 years in ISCHEMIA-CKD extension study
The trial speaks to the lofty high-risk status of patients with CAD. ‘You’re seeing in a group of patients, with largely preserved EF but advanced...
Guidelines
ACC/AHA issue chest pain data standards update to 2021 guideline
The data standards are an effort to harmonize the language around chest pain and should be “broadly applicable,” the work group says.
From the Journals
Artificial sweeteners linked to higher CV event risk
The first study to include artificial sweetener from all sources, not just drinks, may increase concerns about these agents. But not all are...
Opinion
Muscling through the data
Sometimes no amount of solid data will change the mind of someone who’s already made theirs up.
From the Journals
Low physical function tied to cardiac events in older adults
“We found that physical function in older adults predicts future cardiovascular disease beyond traditional heart disease risk factors, regardless...
Conference Coverage
MR and PET perform similarly for assessing CAD
Head-to-head comparison of rubidium PET and cardiac MR showed comparable performance for identifying coronary obstructions.
Conference Coverage
Majority of muscle symptoms with statins not caused by treatment
A new Cholesterol Trialists Collaboration meta-analysis shows that in 14 of the 15 people who experience muscle pain or weakness when taking a...
Conference Coverage
Evolocumab benefits accrue with longer follow-up: FOURIER OLE
Chief among the benefits was a reduction in cardiovascular mortality not observed in the pivotal trial that led to U.S. approval of evolocumab.
Guidelines
ACC fills gaps on guidance for nonstatin therapies for LDL-C lowering
The new guidance addresses the role of nonstatin therapies for lowering LDL-C, which were not addressed in the 2018 ACC/AHA guideline on...
Conference Coverage
No benefit of routine stress test POST-PCI in high-risk patients
Routine functional testing provided no advantage on clinical outcomes over standard care among high-risk patients after intervention, suggesting ‘...